Press Release

For Immediate Distribution

Panacea Biotec Announces Joint Collaboration with Bionpharma Inc.

New Delhi – 28th July 2017: Panacea Biotec, India’s highly progressive research based biotechnology company, has entered into Joint Collaboration for Development, License, Manufacturing, Supply and Sales of 7 complex generic pharmaceutical products with Bionpharma Inc., a generic pharmaceutical company based in the United States.

The key highlights of the joint collaboration are as follows:

- The joint collaboration is established for research, development and manufacturing activities for commercialization of 7 Abbreviated New Drug Applications (ANDAs), which are currently under development at Panacea Biotec, representing a total estimated market potential of more than USD 800 Mn.
- Under the collaboration, Panacea Biotec will be responsible for development, filing, registration, manufacturing & supply of these ANDAs.
- Bionpharma Inc. will be responsible for importation, warehousing, sales and distribution of these ANDAs in the United States and its territories.
- Under this joint collaboration, both companies intend to expand the scope of their alliance by adding new products to the collaboration from time to time.

Under a previous arrangement, Bionpharma is also the exclusive distributor for 2 ANDAs of Panacea Biotec for the US market. These ANDAs have already been commercialized under a separate exclusive license and supply agreement.

Panacea Biotec’s pharmaceutical formulation facility is approved by several International Regulatory Agencies including USFDA, German Authorities, Brazil (ANVISA), Turkey, Serbia, South Africa etc. and its product portfolio has expanded internationally with its products reaching out to more than 33 countries. Panacea Biotec has filed 7 ANDAs out of which 2 have been commercialized. With this joint...
collaboration, Panacea Biotec strives to expand its product portfolio in the US and become a global player in technology based specialty generic pharmaceuticals, applying its formulation and drug delivery expertise.

Commenting on the development, Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec said “This joint collaboration reflects the shared belief between Bionpharma and Panacea Biotec that the development and commercialization of high barrier to entry & complex generics needs significant innovation, technical expertise, infrastructure and investment to achieve the edge in market place”.

About Bionpharma Inc

Bionpharma is a vibrant and fast growing generic pharmaceutical company with a strong commercial portfolio and a pipeline of generic products in the USA. With offices in Princeton, NJ and Raleigh, North Carolina, Bionpharma is one of the largest supplier of Softgel Capsules in the US market with a presence in the prescription and OTC segments of the market. Bionpharma’s focus is on R&D-to develop and commercialize affordable generics in the US market through building strong and effective partnerships.

About Panacea Biotec

Panacea Biotec Limited is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India. The Company has also been ranked amongst the top 25 pharmaceutical companies (AIOCD AWACS-MAT MAR-2016) in represented market India.

The product portfolio of includes highly innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. It is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems.
It has introduced its products in over 33 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations.

The company’s state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with several leading regulatory agencies worldwide. The company has around 2,500 employees including around 120 scientists working across 4 R&D centers of the Company.

For more information, please contact –

For Panacea Biotec
Mr. P. D. Karan
Vice President - Corporate Communication & Business Development
B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,
Mathura Road, New Delhi – 110044, INDIA
Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)
Fax + 91 11 41578002
Mobile: + 91 9312693040, + 91 9810500539
Email: pdkaran@panaceabiotec.com
Web: www.panaceabiotec.com

For Bionpharma
www.bionpharma.com
Serious inquiries only to partners@bionpharma.com